Published date: We reviewed the evidence in November 2018. We found nothing new that affects the recommendations in this guidance.
Published date: We reviewed the evidence in January 2016. We found nothing new that affects the recommendations in this guidance.
Published date: We reviewed the evidence in July 2017. We found nothing new that affects the recommendations in this guidance.
Published date: We reviewed the evidence in March 2018. We found nothing new that affects the recommendations in this guidance.
Published date: Next review: 2020
Published date: In July 2017, we decided that we will review the evidence within 6 months of publication of the PIX306 trial results.
Published date: Next review: 2019
Published date: Next review: 2022
There is a simple discount patient access scheme for pentosan polysulfate sodium
Published date: Next review: 2019 This guidance replaces TA309.
Published date:
We reviewed the evidence in July 2018. We found nothing new that affects the recommendations in this guidance.
Published date: We reviewed the evidence in January 2020. We found nothing new that affects the recommendations in this guidance.
This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza).
Published date: Next review: 2021
Published date: Next review: 2021
Published date: We reviewed the evidence in September 2018. We found nothing new that affects the recommendations in this guidance.
September 2016: The European Medicines Agency has reviewed idelalisib and the marketing authorisation has been updated.
For people taking idelalisib as a first therapy, the marketing authorisation now states that idelalisib is for ‘first-line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies’.
Additional information about infections has been included in the marketing authorisation.